Premarket Gainers as of 9:05 am

|By:, SA News Editor

NVCR +67% on positive data from combination therapy.

STDY +36% on favorable patent ruling.

APOP +15% on grant of patent notice in EU.

DVAX +13% on PDUFA date for HEPLISAV-B remains unchanged.

INFI +11% on updates of Phase 1 data for IPI-549 at the AACR 2017.

IDXG +10% on European Patent Approval For Underlying Technology of its ThyraMIR microRNA Classifier.

ONCS +9% on Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response.

ARTX +8% on receiving a sole source follow-on contract to support the U.S. Army’s Virtual Clearance Training Suite program.

MDGS +8%.

EBIO +7% on new preclinical data.

BCRX +6% on receiving approval for Mundesine in Japan.

BIOC +6%. 

ELOS +5% on acquisition by funds advised by Apax Partners for $11 per share in cash.

KITE +5% ongoing response rate in plenary session from its pivotal CAR-T trial.